Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PRGN-3007 by Precigen for Hematological Tumor: Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Hematological Tumor. According to GlobalData, Phase I...
PRGN-3007 by Precigen for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
PRGN-3007 by Precigen for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
PRGN-3007 by Precigen for Solid Tumor: Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
PRGN-3007 by Precigen for Mantle Cell Lymphoma: Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase...
PRGN-3007 by Precigen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
PRGN-3007 by Precigen for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
PRGN-3007 by Precigen for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
PRGN-2012 by Precigen for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma): Likelihood of Approval
PRGN-2012 is under clinical development by Precigen and currently in Phase II for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or...
PRGN-2009 by Precigen for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
PRGN-2009 is under clinical development by Precigen and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According to...
PRGN-3006 by Precigen for Refractory Acute Myeloid Leukemia: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
PRGN-3006 by Precigen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
PRGN-3006 by Precigen for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...
PRGN-3006 by Precigen for Myelodysplastic Syndrome: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...